Last reviewed · How we verify

NCT00682812

Significance of the High-risk Hpv Viral Load

Completed NA Last updated 24 May 2023
What this trial tests

NA trial testing 2 cervical takings and 2 sampling of blood in HPV Infections in 149 participants. Completed in 23 May 2023.

Timeline
16 June 2008
Primary endpoint
24 April 2014
23 May 2023

Quick facts

Lead sponsorAssistance Publique Hopitaux De Marseille
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment149
Start date16 June 2008
Primary completion24 April 2014
Estimated completion23 May 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

18 and older, female only, with HPV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the significance of an elevated high-risk HPV (HR-HPV) viral load.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HPV Infections

Currently open trials in the same condition.

Other Assistance Publique Hopitaux De Marseille trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00682812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing